Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Tables)

9 Months Ended

Sep. 30, 2014

Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Tables) [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

Calculation of gain from Watson product disposition (in millions)
Consideration received	$	16.8
Intangible assets disposed		(5.9	)
Goodwill disposed		(1.1	)
Other assets disposed		(0.8	)
Pre-Tax Gain recognized	$	9.0

Calculation of gain/from ECR Divestiture (in millions)
Consideration received	$	41.0
Intangible assets divested		(33.6	)
Goodwill divested		(10.4	)
Other assets divested		(1.2	)
Assumed liabilities divested		5.1
Pre-Tax Gain recognized	$	0.9

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended September 30,					Nine Months Ended September 30,
	2014			2013		2014		2013
Revenue	$	139,880		$	148,288	$	489,567	$	430,550
Net income (loss) from continuing operations		(6,562	)		6,296		29,759		(14,698	)
Net income (loss) from continuing operations per share	$	(0.06	)	$	0.06	$	0.25	$	(0.15	)

VersaPharm [Member]

Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Tables) [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Consideration:
Amount of cash paid to VersaPharm Stockholders	$	322.7
Amount of cash paid to vested VersaPharm option holders		14.2
Amounts paid to escrow accounts		10.3
Transaction expenses paid for previous owners of VersaPharm		3.4
Total consideration paid at closing		350.6
VersaPharm debt paid off through closing cash		82.4
Total cash paid at closing		433.0
Recognized amounts of identifiable assets acquired and liabilities assumed:
Cash and cash equivalents	$	0.1
Accounts receivable		10.0
Inventory		20.9
Other current assets		2.8
Property and equipment		1.5
Trademarks		1.0
Product licensing rights		250.8
Intangibles, other		5.2
IPR&D		215.9
Goodwill		90.6
Total assets acquired	$	598.8
Assumed current liabilities		(18.3)
Assumed non-current liabilities		(76.0)
Deferred tax liabilities		(153.9)
Total liabilities assumed	$	(248.2)
	$	350.6

Hi-Tech Pharmacal Co., Inc [Member]

Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Tables) [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Recognized amounts of identifiable assets acquired and liabilities assumed:	Initial Fair Valuation			Measurement Period Adjustments			Adjusted Fair Valuation
Cash and cash equivalents	$	89.7		$	—		$	89.7
Accounts receivable		48.5			(3.5	)		45.0
Inventory		53.7			(0.7	)		53.0
Other current assets		23.9			(0.2	)		23.7
Property and equipment		45.6			(1.8	)		43.8
Product licensing rights		343.5			—			343.5
IPR&D		9.4			—			9.4
Customer Relationships		0.3			—			0.3
Trademarks		5.5			—			5.5
Goodwill		177.1			4.5			181.6
Other non-current assets		0.6			—			0.6
Total assets acquired	$	797.8		$	(1.7	)	$	796.1
Assumed current liabilities		(23.5	)		1.7			(21.8	)
Assumed non-current liabilities		(2.8	)		—			(2.8	)
Deferred tax liabilities		(121.9	)		—			(121.9	)
Total liabilities assumed	$	(148.2	)	$	1.7		$	(146.5	)
	$	649.6		$	—		$	649.6

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

Consideration:	Initial Fair Valuation		Measurement Period Adjustments		Adjusted Fair Valuation
Amount of cash paid to Hi-Tech stockholders	$	605.0	$	—	$	605.0
Amount of cash paid to vested Hi-Tech option holders		40.5		—		40.5
Amount of cash paid to key executives under single-trigger separation payments upon change-in-control		4.1		—		4.1
	$	649.6	$	—	$	649.6

Betimol Acquisition [Member]

Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Tables) [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Betimol Acquisition:
Consideration paid in cash at closing	$	7.5
Purchase consideration payable		4.0
	$	11.5
Fair value of acquired assets:
U.S. NDA rights to Betimol®	$	11.4
Favorable supply agreement		0.1
	$	11.5

Merck Acquisition [Member]

Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Tables) [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Product rights:
AzaSite	$	13.8
Cosopt		21.6
Cosopt PF		20.3
Product rights total	$	55.7
Prepaid expenses		0.1
Deferred tax assets, net		0.7
Total fair value of acquired assets	$	56.5
Consideration paid	$	52.8
Gain from bargain purchase	$	3.7